Independent validation of the PAM50-based chemo-endocrine score (CES) in hormonal receptor positive (HR+)/HER2+ breast cancer (BC) treated with neoadjuvant anti-HER2-targeted therapy
- Citation:
- Ann Oncol vol 31 (Supplement 2) S17
- Meeting Instance:
- ESMO Breast 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Following different anti-HER2 combinations in HR+/HER2+ BC across 8 studies: CHERLOB, OptiHER, LPT109096, ICO, HCB, Per-ELISA and C40601.
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3680
- Pharmas:
- Grants:
- P50-CA58823, R01-CA229409, U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Tomás Pascual Aranzazu Fernandez-Martinez Maki Tanioka M. Vittoria Dieci Sonia Pernas Joaquin Gavila Valentina Guarneri Javier Cortes Patricia Villagrasa Núria Chic Maria Vidal Barbara Adamo Montserrat Muñoz Gaia Griguolo Antonio Llombart Pierfranco Conte Mafalda Oliveira Benedetta Conte Laia Paré Patricia Galvan Lisa Carey Charles M. Perou Aleix Prat
- Networks:
- LAPS-NC007
- Study
- CALGB-40601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: